Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
VIROGIN BIOTECH CANADA LTD. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single action is being examined by 1 distinct examiner, JOHNSON, KARA D. As the only examiner with an active matter, JOHNSON, KARA D is designated as the busiest examiner for the portfolio. The prosecution is currently active within 1 distinct art unit, reflecting a focused technical review.
With 1 pending office action in total, the company's patent efforts are currently concentrated on one specific filing. JOHNSON, KARA D is responsible for 1 pending action, which is the only matter on the current docket. The involvement of 1 distinct art unit allows for a targeted legal strategy tailored to that unit's examination practices. Practitioners should focus on resolving this 1 pending action to advance the company's biotechnology and pharmaceutical intellectual property.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOHNSON, KARA D | 1 | 69.3% | +25.1% |
| BARRERA, IMMACULADA | 1 | 30.0% | +80.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18686229 | ENGINEERED ONCOLYTIC HERPESVIRUSES | JOHNSON, KARA D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18686229 | ENGINEERED ONCOLYTIC HERPESVIRUSES | JOHNSON, KARA D | — |
| 18159473 | ANTI-GLYCOPROTEIN D ANTIBODIES, METHODS OF PREPARATION, AND USES THEREOF | BARRERA, IMMACULADA | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18686229 | ENGINEERED ONCOLYTIC HERPESVIRUSES | JOHNSON, KARA D | 1632 | §102§103§112 | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18159473 | ANTI-GLYCOPROTEIN D ANTIBODIES, METHODS OF PREPARATION, AND USES THEREOF | BARRERA, IMMACULADA | 1671 | §112 | Final Rejection | — | Pending | Jan 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVIROGIN BIOTECH CANADA LTD. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Kara D Johnson has the most, with 1 of VIROGIN BIOTECH CANADA LTD.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
